# Evaluating Fine Needle Aspiration to Measure Hepatic Vaniprevir (MK-7009) Concentrations in Participants With Chronic Hepatitis C (MK-7009-048)

> **NCT01678131** · PHASE1 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 31 (actual)

## Conditions studied

- Chronic Hepatitis C

## Interventions

- **DRUG:** Vaniprevir 600 mg
- **BIOLOGICAL:** Peg-IFN alfa-2b
- **BIOLOGICAL:** Ribavirin
- **PROCEDURE:** Liver samples from FNA
- **DRUG:** Vaniprevir 300 mg
- **PROCEDURE:** Liver samples from CNB

## Key facts

- **NCT ID:** NCT01678131
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-10-30
- **Primary completion:** 2013-08-27
- **Final completion:** 2013-09-02
- **Target enrollment:** 31 (ACTUAL)
- **Last updated:** 2022-08-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01678131

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01678131, "Evaluating Fine Needle Aspiration to Measure Hepatic Vaniprevir (MK-7009) Concentrations in Participants With Chronic Hepatitis C (MK-7009-048)". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT01678131. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*